Electronic Warning System for Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Electronic Warning System to Improve Stroke Prevention in Atrial Fibrillation - A Quality Improvement Initiative at the University Hospital Bern

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02455102
• Other study ID #: 022/14
• Status: Completed
• Phase: N/A
• First received: May 6, 2015
• Last updated: December 21, 2015
• Start date: September 2014
• Est. completion date: October 2015

Study information

• Verified date: December 2015
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The aim of this randomized controlled study is to evaluate whether a newly designed electronic warning system will increase the initiation rate of adequate stroke preventive measures in patients with atrial fibrillation.

Description:

A large proportion of patients with atrial fibrillation do not receive stroke prevention therapy in line with the guidelines, in spite of the presence of an increased risk of stroke. It will be investigated whether an electronic alert to physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will increase the rate of adequate stroke preventive measures as compared to a control group of patients without an electronic alert. The electronic alerts will be sent if patients with atrial fibrillation but without adequate stroke preventive measures receive in-patient treatment at the University Hospital Bern. The electronic alert system includes a feature that helps the physicians in charge to evaluate the CHA2DS2VASC Score. At the end of the hospital stay medical discharge letters will be reviewed for initiation of adequate stroke preventive measures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1707
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All in-patients with atrial fibrillation

Exclusion Criteria:

• Ongoing anticoagulant therapy

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Other:
• Electronic warning alert
A newly-installed warning system for stroke prevention in atrial fibrillation.

Locations

Country	Name	City	State
Switzerland	Swiss Cardiovascular Center, Inselspital, University of Bern	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of initiation of adequate measures to prevent stroke (oral anticoagulant prescription) by physician in charge	Reviewed from discharge letter	End of hospital stay (expected average duration of 1 week)	No
Secondary	Use of the CHA2DS2VASc score calculation tool by the physician in charge		During hospital stay (expected average duration of 1 week)	No
Secondary	Rate of correct evaluation of the CHA2DS2VASC Score through the calculation tool by physician in charge		End of hospital stay (expected average duration of 1 week)	No